News Feature | November 17, 2026

Don't Discard Your Animal Data Yet

Source: Drug Discovery Online

By Morgan Kohler, Executive Editor

No dumping trash garbage refuse recycle trash-GettyImages-2233821585

Policy direction on animal testing seems to be settled; however, the validation standard remains unresolved. This gap is where preclinical programs are currently exposed.

An article published this month in The Innovation assesses how far new approach methodologies (NAMs) can take over from animal models. These researchers, from Zhejiang University and Hangzhou City University, argue for a staged transition that maximizes the value of existing animal data while human-relevant models are verified against it. They situate their analysis against the FDA’s April 2025 announcement that it would phase out mandatory animal testing for certain therapeutics, beginning with monoclonal antibodies, with the NIH and the European Medicines Agency promoting alternatives in parallel.

Their position is narrower than it first appears. The authors aren’t arguing that organoids, organ-on-a-chip systems, and AI models cannot replace animal studies. Rather, their argument is about sequence — the credibility of a NAM package currently derives from comparison against animal data, which makes legacy in vivo studies a validation resource rather than a sunk cost. That framing has a practical consequence most organizations have not acted on: The value of a NAM submission may depend on data a company generated years ago and filed in a form nobody can retrieve.

What This Means For Drug Discovery

The FDA’s draft guidance General Considerations for the Use of New Approach Methodologies in Drug Development, published in the Federal Register on March 19, 2026, under docket FDA-2025-D-6131, sets out a validation framework for NAM data in submissions. It also states explicitly that it does not address specific NAMs and does not address the use of NAMs in drug discovery — a scope limit that teams can easily miss if they assume the guidance covers their discovery-stage work.

The agency followed with a direct final rule on Sept. 21, 2026, clarifying that nonanimal methods may be used where appropriate for testing the safety of drugs and biologics before human trials. That rule does not eliminate or prohibit animal studies and does not change evidentiary standards. It arrived alongside a database of NAM uses drawn from public FDA review materials, with an initial release of 25 examples. On the oncology side, a draft guidance issued May 29, 2026, recommends eliminating unnecessary animal testing, using a single relevant species instead of two, or replacing animal studies with evidence-based approaches for biologics and conjugated products.

Read together, these are permissions and not substitutions. Every one of them retains weight-of-evidence framing, and the burden of demonstrating relevance sits with the sponsor.

A NAM is qualified for a context of use, not in general. An organ-on-a-chip system that is fit for purpose on airway permeability establishes nothing about a hepatotoxicity question. Sponsors who read the FDA's April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies as license to drop studies are reading past the context-of-use requirement, which governs whether their package survives review.

Toxicology, regulatory affairs, CRO management, and discovery biology must agree on which NAM data get generated early enough to inform a decision. A microphysiological system result that arrives after candidate selection is a validation exercise and not a decision input. Compounding this, method qualification varies widely among CRO vendors, so the same assay purchased from two suppliers may not carry the same evidentiary weight.

The realistic near-term shift is in early safety triage rather than IND-enabling packages, such as using human-relevant systems to deprioritize chemotypes before committing to GLP studies. That moves absorption, distribution, metabolism, excretion, and toxicity (ADMET) and early toxicology questions earlier into lead optimization and changes what data a team needs in hand at candidate selection.

Programs whose timelines or budgets already book savings from reduced animal studies should re-examine that assumption now against the weight-of-evidence language, the context-of-use requirement, and the central NAM guidance's silence on discovery-stage use.

The most useful contribution from the earlier-mentioned article is that teams that archived control-group and comparator data in retrievable form (the underlying study-parameter data) are materially better positioned to demonstrate concordance when they propose a NAM for a specific context of use. Organizations that archived their data this way may qualify their methods faster than those that spent the same period buying equipment.

The Preclinical Question

Could you retrieve your historical in vivo data at the study-parameter level today, or only the reports?

Related Drug Discovery Online Editorials

About The Editor

Morgan Kohler is the executive editor of guest expert articles for Drug Discovery Online, working with industry experts to develop insightful and informative pieces about drug discovery and preclinical drug development science, regulatory strategy, trends, analyses, and commentary.

Morgan holds a master’s degree in professional writing and web content development and has worked in the publishing industry since 2018. Before working for Drug Discovery Online, she guided and edited industry-expert-bylined content on topics related to radiology and economics.